| abstract |
This invention features an Aiolos gene and polypeptide. The Aiolos polypeptide has a molecular weight of approximately 58 kd and has an N-terminal zinc finger domain. The Aiolos gene is expressed in committed lymphoid progenitors as well as in T and B cells. Therapies for disorders of the immune system, T or B cell related disorders, asthma, or immune mediated skin disorders are presented. Transgenic animals are provided with an Aiolos transgene. |